Arena (ARNA) Inches Higher Follow CEO Comments
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals's (Nasdaq: ARNA) CEO told CNBC he sees Belviq as "transformative." In response, shares inched higher in after-hours trading on Tuesday. BELVIQ is a weight loss drug approved by the US Food and Drug Administration for use in adults who are obese.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morningstar Q&A: AI Pricing, PitchBook Growth and Private Markets
- Rosenblatt Assumes Marvell (MRVL) at Buy
- Rosenblatt Reiterates Buy Rating on NVIDIA (NVDA) into Earnings
Create E-mail Alert Related Categories
Management CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
